BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s $8 billion acquisition,  much of the activity is taking place in China, where a short list of dominant cancers, out-of-pocket spending habits...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...an internal rate of return of about 12%. Scioto raises up to $26.5MKorean microbiome play Genome & Co....
BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

Despite the high-profile nature of the patent dispute between Illumina and Chinese competitor BGI Genomics, two of the largest players in next-generation sequencing, there is no reason to believe it will become embroiled in the...
BioCentury | Mar 28, 2020
Product Development

COVID-19 roundup: FDA approves Abbott’s 5-minute test; plus Trump signs stimulus bill, WHO readies master protocol, CytoDyn mAb data and more

FDA granted emergency approval Friday to a trio of diagnostics for COVID-19, including a molecular point-of-care test from Abbott that can detect COVID-19 in minutes. The approvals came as President Donald Trump signed a $2...
BioCentury | Mar 19, 2020
Product Development

BGI, Quidel launch COVID-19 diagnostics while HHS funds Mesa’s point-of-care test

Industry is continuing to ramp up COVID-19 testing capacity to meet demand, as two diagnostics enter the U.S. market and HHS’s BARDA grants its fourth award for a COVID-19 assay. BGI Genomics Co. Ltd. (SZSE:300676)...
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

Wednesday saw a full slate of clinical updates across the globe for vaccine and therapeutic candidates to address COVID-19, while HHS launched a new public-private partnership to ramp up emergency drug packaging capabilities. Roivant Sciences...
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

Migraine drug marks Biohaven’s first FDA approval Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced after market close that FDA approved NURTEC ODT rimegepant as an acute treatment for migraine, marking the company’s first U.S. approval....
BioCentury | Feb 6, 2020
Product Development

2019-nCoV diagnostics ramp up in China, globally

Companies and government organizations have started large-scale deployment of diagnostics to diagnose and screen for 2019-nCoV. If secondary transmission of the virus occurs on a large scale outside China, diagnostics will be essential for effective...
BioCentury | Jun 14, 2019
Politics & Policy

June 14 P&P Quick Takes: Washington state approved for subscription HCV model; plus Merck and IBM, BGI, and more

Washington follows Louisiana in creating 'Netflix' model to buy HCV drugs CMS approved Washington's Medicaid state plan amendment proposal to establish a subscription-based model for HCV drugs, under which the state would pay a fixed...
BioCentury | Jun 11, 2019
Politics & Policy

Senators call for HHS probe into CMS genetic testing payments to Chinese-linked companies

Sens. Charles Grassley (R-Iowa) and Marco Rubio (R-Fla.) have asked the HHS inspector general to investigate payments made by CMS to U.S. genetic testing companies that are partnered with companies that have ties to Beijing....
Items per page:
1 - 10 of 51
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s $8 billion acquisition,  much of the activity is taking place in China, where a short list of dominant cancers, out-of-pocket spending habits...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...an internal rate of return of about 12%. Scioto raises up to $26.5MKorean microbiome play Genome & Co....
BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

Despite the high-profile nature of the patent dispute between Illumina and Chinese competitor BGI Genomics, two of the largest players in next-generation sequencing, there is no reason to believe it will become embroiled in the...
BioCentury | Mar 28, 2020
Product Development

COVID-19 roundup: FDA approves Abbott’s 5-minute test; plus Trump signs stimulus bill, WHO readies master protocol, CytoDyn mAb data and more

FDA granted emergency approval Friday to a trio of diagnostics for COVID-19, including a molecular point-of-care test from Abbott that can detect COVID-19 in minutes. The approvals came as President Donald Trump signed a $2...
BioCentury | Mar 19, 2020
Product Development

BGI, Quidel launch COVID-19 diagnostics while HHS funds Mesa’s point-of-care test

Industry is continuing to ramp up COVID-19 testing capacity to meet demand, as two diagnostics enter the U.S. market and HHS’s BARDA grants its fourth award for a COVID-19 assay. BGI Genomics Co. Ltd. (SZSE:300676)...
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

Wednesday saw a full slate of clinical updates across the globe for vaccine and therapeutic candidates to address COVID-19, while HHS launched a new public-private partnership to ramp up emergency drug packaging capabilities. Roivant Sciences...
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

Migraine drug marks Biohaven’s first FDA approval Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced after market close that FDA approved NURTEC ODT rimegepant as an acute treatment for migraine, marking the company’s first U.S. approval....
BioCentury | Feb 6, 2020
Product Development

2019-nCoV diagnostics ramp up in China, globally

Companies and government organizations have started large-scale deployment of diagnostics to diagnose and screen for 2019-nCoV. If secondary transmission of the virus occurs on a large scale outside China, diagnostics will be essential for effective...
BioCentury | Jun 14, 2019
Politics & Policy

June 14 P&P Quick Takes: Washington state approved for subscription HCV model; plus Merck and IBM, BGI, and more

Washington follows Louisiana in creating 'Netflix' model to buy HCV drugs CMS approved Washington's Medicaid state plan amendment proposal to establish a subscription-based model for HCV drugs, under which the state would pay a fixed...
BioCentury | Jun 11, 2019
Politics & Policy

Senators call for HHS probe into CMS genetic testing payments to Chinese-linked companies

Sens. Charles Grassley (R-Iowa) and Marco Rubio (R-Fla.) have asked the HHS inspector general to investigate payments made by CMS to U.S. genetic testing companies that are partnered with companies that have ties to Beijing....
Items per page:
1 - 10 of 51